Spore in lung cancer

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Spore in lung cancer
Principal Investigators (PI): BAYLIN STEPHEN B
Project Number: 5P50CA058184-08
Organization: JOHNS HOPKINS UNIVERSITY
 
Project Description:
The Johns Hopkins SPORE program for lung cancer, functioning as a major element of the Johns Hopkins Comprehensive Cancer Center, would represent a multidisciplinary and highly collaborative translational research effort to develop new strategies for early detection, prevention and treatment of lung cancer. Included will be an emphasis upon enhancing entry of new investigators into careers in lung cancer research -- and encouragement of novel research approaches through funding of pilot projects. The work scope of the SPORE addresses most of the research imperatives defined at the 1991 Annapolis Lung Cancer Workshop. A major emphasis is devoted to defining, at a molecular level, the earliest steps in lung cancer evolution. The goal is to develop markers which will be tested for efficacy in predicting and/or detecting early lung cancer and which will serve as new tools for guiding prevention and early treatment strategies. Unique tissue acquisition efforts of a Core Tissue Resource will allow isolated fresh and cultured human bronchial epithelium to be studied for timing of genetic (allelic losses, gene mutations) and epigenetic (changes in DNA methylation, neuroendocrine differentiation, signal transduction events, monoclonal antibody recognition) abnormalities in lung cancer progression. The research will include studies of unique patient cohorts for lung cancer risk, including uranium miners and individuals at genetic risk, and studies of unique rodent models for lung cancer induction. Novel treatment strategies for lung cancer, based on molecular targets defined in the laboratory, will be evaluated in focused clinical trials. Included will be molecular biology and biochemical assays to predict and monitor responses. Novel polyamine analogues active, through a newly defined gene induction event, against non-small cell lung cancer (NSCLC) will receive an initial clinical trial. The observation that retinoids can block a tumor progression step for small cell lung cancer cells, in a laboratory model, will be translated into a clinical trial to prevent, or delay, drug resistance for this cancer. In summary, this SPORE program represents an exciting collaborative opportunity for basic and clinical investigators to translate understanding of fundamental biology into new means to prevent, detect and treat lung cancer.
 
Project Terms:
lung neoplasms neoplasm /cancer genetics molecular oncology
Project Title: Spore in lung cancer
Principal Investigators (PI): BAYLIN STEPHEN B
Project Number: 5P50CA058184-08
Organization: JOHNS HOPKINS UNIVERSITY
 
Project Categories:
• Natural Sciences > Aging Diseases and Pathology > Cancer & related diseases > Malignant neoplasms (including in situ) > Lung cancer
 
Other Information:
Fiscal Year: 1992
Project Start Date: 30 September 1992
Project End Date: 31 May 2003
Administering Institute Or Center: CA
 
Project Funding Information:
Total Funding: $1,776,628
Year Funding Organization Total Funding, $
2000 NATIONAL CANCER INSTITUTE $1,776,628
Project Title: Spore in lung cancer
Principal Investigators (PI): BAYLIN STEPHEN B
Project Number: 5P50CA058184-08
Organization: JOHNS HOPKINS UNIVERSITY
 
Project number Project title Organization FY Funding Organization FY Total Cost
2R01CA043318-19Methylation of the Calcitonin Gene in Human TumorsJOHNS HOPKINS UNIVERSITY2004NATIONAL CANCER INSTITUTE
$449,625
5P50CA058184-10SPORE in Lung CancerJOHNS HOPKINS UNIVERSITY2004NATIONAL CANCER INSTITUTE
$2,491,531
5R01CA043318-18METHYLATION OF THE CALCITONIN GENE IN HUMAN TUMORSJOHNS HOPKINS UNIVERSITY2003NATIONAL CANCER INSTITUTE
$435,948
2P50CA058184-09SPORE in Lung CancerJOHNS HOPKINS UNIVERSITY2003NATIONAL CANCER INSTITUTE
$2,500,000
5R01CA043318-17METHYLATION OF THE CALCITONIN GENE IN HUMAN TUMORSJOHNS HOPKINS UNIVERSITY2002NATIONAL CANCER INSTITUTE
$424,197
3P50CA058184-08S2SPORE IN LUNG CANCERJOHNS HOPKINS UNIVERSITY2002NATIONAL CANCER INSTITUTE
$1,826,707
5R01CA043318-16METHYLATION OF THE CALCITONIN GENE IN HUMAN TUMORSJOHNS HOPKINS UNIVERSITY2001NATIONAL CANCER INSTITUTE
$412,892
3P50CA058184-08S1SPORE IN LUNG CANCERJOHNS HOPKINS UNIVERSITY2001NATIONAL CANCER INSTITUTE
$1,829,926
5R01CA054396-10DNA METHYLTRANSFERASE GENE EXPRESSION IN COLON CANCERJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$362,833
5R01CA043318-15METHYLATION OF THE CALCITONIN GENE IN HUMAN TUMORSJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$402,935
5P50CA058184-08-0011LUNG CANCER--CAREER DEVELOPMENTJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$131,614
5P50CA058184-08-0002DNA METHYLATION/NEUROENDOCRINE DIFFERENTIATION--MARKING EARLY STATE LUNG CANCERJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$131,614
5P50CA058184-08-0010LUNG CANCER--DEVELOPMENTAL RESEARCH PROGRAMJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$131,614
5P50CA058184-08SPORE IN LUNG CANCERJOHNS HOPKINS UNIVERSITY2000NATIONAL CANCER INSTITUTE
$1,776,628
5P50CA058184-11SPORE in Lung CancerJOHNS HOPKINS UNIVERSITY2005NATIONAL CANCER INSTITUTE
$2,490,165
5R01CA043318-20Methylation of the Calcitonin Gene in Human TumorsJOHNS HOPKINS UNIVERSITY2005NATIONAL CANCER INSTITUTE
$449,625
1R01CA116160-01Developmental pathways, cancer, and DNA hypermethylationJOHNS HOPKINS UNIVERSITY2005NATIONAL CANCER INSTITUTE
$321,678
2P30CA006973-44-0002PROGRAM LEADERSHIPJOHNS HOPKINS UNIVERSITY2006NATIONAL CANCER INSTITUTE
$285,854
2P30CA006973-44-9035MICROARRAYJOHNS HOPKINS UNIVERSITY2006NATIONAL CANCER INSTITUTE
$95,328
2P30CA006973-44-9047CRCJOHNS HOPKINS UNIVERSITY2006NATIONAL CANCER INSTITUTE
$48,571
Project Title: Spore in lung cancer
Principal Investigators (PI): BAYLIN STEPHEN B
Project Number: 5P50CA058184-08
Organization: JOHNS HOPKINS UNIVERSITY
 
Project number Project title Principal investigator
There are no any related projects.
Project Title: Spore in lung cancer
Principal Investigators (PI): BAYLIN STEPHEN B
Project Number: 5P50CA058184-08
Organization: JOHNS HOPKINS UNIVERSITY
 
Title Abstract Authors Year Rel
Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer research.. 2000 Jun 15 60 (12) :3155-9 Ahrendt, S A; Chow, J T; Yang, S C; Wu, L; Zhang, M J; Jen, J; Sidransky, D 2000
Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. International journal of cancer. Journal international du cancer. 2000 Jun 1 86 (5) :684-9 Yamaguchi, K; Wu, L; Caballero, O L; Hibi, K; Trink, B; Resto, V; Cairns, P; Okami, K; Koch, W M; Sidransky, D; Jen, J 2000
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (New York, N.Y.). 2000 Mar 17 287 (5460) :2017-9 Fliss, M S; Usadel, H; Caballero, O L; Wu, L; Buta, M R; Eleff, S M; Jen, J; Sidransky, D 2000
Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer research.. 2000 May 1 60 (9) :2488-91 Ahrendt, S A; Decker, P A; Doffek, K; Wang, B; Xu, L; Demeure, M J; Jen, J; Sidransky, D 2000
Assignment of BUB3 to human chromosome band 10q26 by in situ hybridization. Cytogenetics and cell genetics.. 2000 88 (4-Mar) :202-3 Kwon, T K; Hawkins, A L; Griffin, C A; Gabrielson, E 2000
An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Annals of the New York Academy of Sciences.. 2000 Apr 906 () :12-Aug Jen, J; Wu, L; Sidransky, D 2000
c-Myc suppresses the tumorigenicity of lung cancer cells and down-regulates vascular endothelial growth factor expression. Cancer research.. 2000 Jan 1 60 (1) :143-9 Barr, L F; Campbell, S E; Diette, G B; Gabrielson, E W; Kim, S; Shim, H; Dang, C V 2000
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer research.. 2000 Nov 1 60 (21) :5954-8 Palmisano, W A; Divine, K K; Saccomanno, G; Gilliland, F D; Baylin, S B; Herman, J G; Belinsky, S A 2000